Treatment of stage IV colorectal carcinoma in elderly patients

Critical Reviews in Oncology/Hematology

Volumn 54, Issue 2, 2005, Pages 145-155

  Pasetto, Lara Maria ^a   Stefano, Tamberi ^b   Rossi, Elena ^a   Paris, Myriam Katya ^a   Monfardini, Silvio ^a,c,d  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Medical Oncology Service   (Italy)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d SIOG   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Elderly; Review; Stage IV

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; CAPECITABINE; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; INDOMETACIN; IRINOTECAN; MANNITOL; METHOTREXATE; METRONIDAZOLE; MISONIDAZOLE; NEOMYCIN; OXALIPLATIN; PHENOBARBITAL; PROBENECID; RALTITREXED; SALICYLIC ACID; TETRACYCLINE; UFT; UNINDEXED DRUG; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANEMIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC TOXICITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; LUNG DISEASE; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ONCOLOGY; PNEUMOTHORAX; REVIEW; SENESCENCE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TOXICITY;

EID: 17444432597     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.12.003     Document Type: Review

References (86)

1. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics Cancer J Clin 49 1999 8 31
2. L.C. Walter, and K.E. Corvinsky Cancer screening in elderly patients: a framework for individualized decision making JAMA 285 2001 2750 2756
3. J.M. Jessup, L.S. McGinnis, G.D. Steele, H.R. Menck, and D.P. Winchester The National Cancer Data Base. Report on colon cancer Cancer 78 1996 918 926
4. H. Kohne, A. Grothey, C. Bekemeyer, N. Bontke, and M. Aapro Chemotherapy in elderly patients with colorectal cancer Ann Oncol 12 2001 435 442
5. L. Grobovsky, M. Kaplon, A. Krozser-Hamati, and A. Karnard Features of cancer in frail elderly patients (pts) (85 years of age) Proc Am Soc Clin Oncol 18 2000 139 [abstr 2469]
6. E.L. Trimble, C.L. Carter, D. Cain, B. Freidlin, R.S. Ungerleidr, and M.A. Friedman Representation of older patients in cancer treatment trials Cancer 74 Suppl. 7 1994 2208 2214
7. O. Hessman, L. Bergkvist, and S. Strom Colorectal cancer in patients over 75 years of age - determinants of outcome Eur J Surg Oncol 23 1 1997 13 19
8. T. Koperna, M. Kisser, and F. Schulz Hepatic resection in the elderly World J Surg 22 4 1998 406 412
9. J.T. Makela, H. Kiviniemi, and S. Laitinen Survival after operations for colorectal cancer in patients aged 75 years or over Eur J Surg 166 6 2000 473 479
10. S.M. Lichtman, and J.A. Skirvin Pharmacology of antineoplastic agents in older cancer patients Oncology (Huntingt) 14 2000 1743 1755
11. T.J. Vogl, P.K. Muller, M.G. Mack, R. Straub, K. Engelmann, and P. Neuhaus Liver metastases: interventional therapeutic techniques and results, state of the art Radiology 9 4 1999 675 684
12. A. De Gramont, J.F. Bosset, and C. Milan Randomised trial comparing monthly low dose leucovorin and 5-fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus continuous infusion for advanced colorectal cancer: a French Intergroup Study J Clin Oncol 15 2 1997 808 815
13. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
14. J.Y. Douillard, D. Cunnimgham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicenter randomised trial Lancet 355 2000 1041 1047
15. S. Giacchetti, B. Perpoint, and R. Zidani Phase III multicenter randomised trial of oxaliplatin added to chrono-modulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
16. A. De Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 2938 2947
17. N. Tsavaris, C. Kosmas, and M. Vadiaka Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients Med Sci Monit 8 6 2002 51 57
18. C.C. Meyer, K.A. Calis, L.B. Burke, C.A. Walawander, and T.H. Grasela Symptomatic cardiotoxicity associated with 5-fluorouracil Pharmacotherapy 17 4 1997 729 736
19. A. Sobrero, A. Guglielmi, and M. Cirillo 5-Fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer Br J Cancer 84 8 2001 1023 1028
20. R. Mattioli, P. Lippe, and F. Recchia Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion Anticancer Res 21 1A 2001 489 492
21. M. Beretta, M. Buonadonna, and S. Rupolo Comparison between elderly and non-elderly patients (pts), of efficacy and tolerability of FOLFOX2 schedule in advanced colorectal cancer (COL) Proc Am Soc Clin Oncol 19 2001 111 [abstr 2195]
22. R.A. Popescu, A. Norman, P.J. Ross, B. Parikh, and D. Cunningham Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older J Clin Oncol 17 8 1999 2412 2418
23. D.J. Sargent, R.M. Goldberg, and S.D. Jacobson A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients N Engl J Med 345 15 2001 1091 1097
24. M. Streit, U. Jaehde, and S. Stremetzne Five days continuous infusion of 5-fluorouracil and pulsed FA in patients with metastatic colorectal carcinoma: an effective second-line regimen Ann Oncol 8 11 1997 163 165
25. J.T. Hartmann, C.H. Kohne, H.J. Schmoll, T. Daikeler, L. Kanz, and C. Bokemeyer Is continuous 24-hour infusion of 5-fluorouracil plus high dose folinic-acid effective in patients with progressive or recurrent colorectal cancer? A phase II study Oncology 55 4 1998 320 325
26. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
27. S. Chiara, M.T. Nobile, and M. Vincenti Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy Cancer Chemother Pharmacol 42 4 1998 336 340
28. M. Mabro, V. Gilles-Amar, and C. Louvet Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients Rev Med Interne 20 10 1999 863 868
29. J.l. Grem Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin Semin Oncol 24 Suppl. 18 1997 8 18
30. G. Beretta, R. Bolina, and C. Cozzi Should we consider the weekly chemotherapy with Fluorouracil + racemic FA a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proc Am Soc Clin Oncol 15 1997 259 [abstr 1040]
31. C.B. Begg, and P.P. Carbone Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group Cancer 52 1986-1992
32. S. Monfardini, R. Sorio, G.H. Boes, S. Kaye, and D. Serraino Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new drug development studies Cancer 76 1995 333 338
33. B.N. Stein, N.J. Petrelli, H.O. Douglass, D.L. Driscoll, G. Arcangeli, and N.J. Meropol Age and sex are indipendent predictors of 5-FU toxicity. Analysis of a large scale phase III trial Cancer 75 1995 11 17
34. G. Folprecht, D. Cunningham, and P. Ross Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann Oncol 15 9 2004 1330 1338
35. G. Milano, M.C. Etienne, and E. Cassuto-Viguier Influence of sex and age on fluoruracil clearance J Clin Oncol 10 1992 1171 1175
36. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 2001 4097 4106
37. K. Wellington, and K.L. Goat Oral tegafur/uracil Drugs Aging 18 12 2001 935 948
38. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study J Clin Oncol 19 8 2001 2282 2292
39. J.V. Cox, R. Pazdur, and A. Thibault A phase III trial of Xeloda™ (capecitabine) in previously untreated advanced/metastatic colorectal cancer Proc Am Soc Clin Oncol 17 1999 264 [abstr 1016]
40. C. Twelves Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials Eur J Cancer 38 2002 15 20
41. G. Liu, E. Franssen, and M.I. Fitch Patients preference for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
42. J. Feliu, M. Gonzalez Baron, and E. Espinosa Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group Cancer 79 10 1997 1884 1889
43. M. Borner, P. Schoffshi, and R. De Wit A randomised crossover trial comparing oral UFT (uracil/tegafur) + LV and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer Proc Am Soc Clin Oncol 18 2000 191 [abstr 741]
44. R. Pazdur, J.Y. Douillard, and J. Skilling Multicenter phase III trial of 5-fluorouracil or UFT in combination with leucovorin in patients with previously untreated metastatic colorectal cancer Proc Am Soc Clin Oncol 17 1999 263 [abstr 1009]
45. J. Carmichael, T. Popiela, and D. Radstone Randomised comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20 17 2002 3617 3627
46. J. Feliu, M. Gonzalez Baron, and E. Espinosa Uracill and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Collaborative Group Cancer 79 1997 1884 1889
47. A. Abad UFT plus folinic acid as therapy for metastatic colorectal cancer in older patients Oncology 11 1999 53 57
48. E. Diaz-Rubio, J. Sastre, and A. Abad UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients Oncology 13 1999 35 40
49. A. Romiti, G. Tonini, and D. Santini Tolerability of raltitrexed (tomudex) in elderly patients with colorectal cancer Anticancer Res 22 5 2002 3071 3076
50. J. Feliu, J.R. Mel, and C. Camps Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen Eur J Cancer 38 9 2002 1204 1211
51. F. Franchi, C. Pastore, A. Caporale, O. Fabiani, L. Rossi, and P. Seminara Favorable toxicity profile of raltitrexed in elderly patients treated for colorectal cancer: a case series Gerontology 49 5 2003 324 327
52. T.S. Maughan, R.D. James, and D.J. Kerr Comparison of survival, palliation, and QOL with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial Lancet 359 2002 1555 1563
53. C.H. Kohne, P. Thuss-Patience, and M. Friederich Raltitrexed (tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity Br J Cancer 77 1998 973 977
54. R. Labianca, G. Beretta, M. Clerici, P. Fraschini, and G. Luporini Cardiac toxicity of 5-fluorouracil: a study on 1083 patients Tumori 68 1982 505 510
55. J. Zalcberg, D. Kerr, L. Seymour, M. Palmer Tomudex International Study Group Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associted with gender, increasing age and cycle number Eur J Cancer 34 1998 1871 1875
56. M. DeParades, J.R. Mel, and P.P. Escudero An ongoing phase II study of tomudex (raltitrexed) in elderly patients with advanced colorectal cancer: an assessment of tolerability and clinical benefit Proc Am Soc Clin Oncol 17 1999 332 [abstr 1332]
57. L.B. Schaaf, N. Icchpurani, and G.L. Elfring Influence of age on the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38 glucuronide, in patients with previously treated colorectal cancer Proc Am Soc Clin Oncol 16 1998 202 [abstr 808]
58. M.L. Rothenberg, J.V. Cox, and R.F. DeVore A multicenter, phase II trial of weekly irinotecan (CPT11) in patients with previously treated colorectal carcinoma Cancer 85 1999 786 795
59. J. Sastre, E. Marcuello, B. Massuti Preliminary results of a Spanish Digestive Group Study CPT11 + 48h 5FU continuous infusion as first line chemotherapy for elderly patients with metastaic colorectal cancer. Proc Am Soc Clin Oncol 22 2003 331 [abstr 1329]
60. E. Mitry, J.Y. Douillard, and E. Van Cutsem Predictive factors of survival in patients with advanced colorectal cancer. An individual data analysis of 602 patients included in CPT1 phase II trilas (V302 and V303) Proc Am Soc Clin Oncol 21 2003 295 [abstr 1184]
61. P. Rougier, E. Mitry, and D. Cunnigham Is age a prognostic factor of toxicity and efficacy in patients with metastatic colorectal cancer receiving irinotecan in combination with 5FU/folinic acid (FA) Proc Am Soc Clin Oncol 21 2003 267 [abstr 1072]
62. R. Bollina, G. Beretta, and D. Toniolo Capiri: a good combination regimen in first line elderly CRC patients Proc Am Soc Clin Oncol 21 2003 332 [abstr 1332]
63. P. Rougier, E. Van Cutsem, and E. Bajetta Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
64. B.D. Minky, E.M. O'Reilly, and D. Wong Daily low dose irinotecan (CPT11) plus pelvic irradiation as preoperative treatmnt of locally advanced rectal cancer Proc Am Soc Clin Oncol 17 1999 265 [abstr 1023]
65. M. Extermann, G. Albrand, and H. Chen Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21 17 2003 3214 3219
66. C. Garufi, A. Pietrangeli, and S. Brienza Electrophysiological evaluation of oxaliplatin neurotoxicity Proc Am Soc Clin Oncol 17 1999 245 [abstr 938]
67. D. Machover, B. Delmas-Marsalet, and S.C. Misra Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma Ann Oncol 12 10 2001 1439 1443
68. Y. Becouarn, M. Ychou, and M. Ducreux Phase II trial of oxaliplatin as I line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of cancer centres J Clin Oncol 16 1998 136 147
69. F. Levi, J.L. Misset, and S. Brienza A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer Cancer 69 4 1992 893 900
70. T. Andrè, M.A. Bensmaine, and C. Louvet Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin d fluorouracil regimen J Clin Oncol 17 1999 3560 3568
71. S. Mosconi, S. Cascinu, and A. Zaniboni The value of oxaliplatin in combination with continuous infusion ± bolus 5FU and levo-folinic acid in metastatic colorectal progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) Tumori 86 6 2000 465 469
72. A. Jirillo, M.K. Paris, E. Rossi, and S. Monfardini Elderly cancer patients observed during one year in a division of medical oncology IV Meeting of International Society of Geriatric Oncology (SIOG) 2003 [abstr 20]
73. H. Gómez, L. Mas, and L. Casanova Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing haematologic toxicity J Clin Oncol 16 1998 2352 2358
74. G.H. Lyman, N.M. Kuderer, and L. Balducci Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients Curr Opin Haematol 9 2002 207 214
75. L. Repetto, L. Biganzoli, and C.H. Koehne EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer Eur J Cancer 39 16 2003 2264 2272
76. J. Crawford, D.C. Dale, and G.H. Lyman Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 2 2004 228 237
77. G.H. Lyman, N. Kuderer, O. Agboola, and L. Balducci Evidence-based use of colony-stimulating factors in elderly cancer patients Cancer Control 10 6 2003 487 499
78. L. Balducci, and G. Yates General guidelines for the management of older patients with cancer Oncology 2000 221 227
79. L. Balducci, and G.H. Lyman Patients aged ≥70 are at high risk for neutropenic infection and should receive haemopoietic growth factors when treated with moderately toxic chemotherapy J Clin Oncol 19 2001 1583 1585
80. S.M. Lichtman Chemotherapy in the elderly Semin Oncol 31 2 2004 160 174
81. P.A. Routledge, M.S. O'Mahony, and K.W. Woodhouse Adverse drug reactions in elderly patients Br J Clin Pharmacol 57 2 2004 121 126
82. R.J. McKenna Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up Cancer 74 7 Suppl. 1994 2107 2117
83. S.B. Yellen, D.F. Cella, and W.T. Leslie Age and clinical decision making in oncology patients J Natl Cancer Inst 86 23 1994 1766 1770
84. L. Fratino, D. Serraino, E. Rossi, S. Lonardi, and S. Monfardini Survival of elderly patients with metastatic colorectal cancer is improved by inclusion in phase II trials IV Meeting of International Society of Geriatric Oncology (SIOG) 2003 [abstr 74]
85. M. Extermann, J. Overcash, G.H. Lyman, J. Parr, and L. Balducci Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
86. S.M. Lichtman Integration of geriatrics in oncology training - the relationship between the academic centre and the community Crit Rev Oncol Haematol 33 2000 57 59